Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia

NCT00487942 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00487942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00487942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
December 31, 2007
Enrollment
60 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia